EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ERAS: Erasca Inc

26 Dec 25 15:59
LAST:

3.485

CHANGE:
 0.05		OPEN:
3.460		HIGH:
3.510		ASK:
0.000		VOLUME:
751.0K
CHG(%):
1.46		PREV:
3.430		LOW:
3.355		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Dec 253.4303.5003.3603.4801.0M
24 Dec 253.3803.5303.3703.4301.23M
23 Dec 253.6103.6413.3203.3902.93M
22 Dec 253.4703.7153.4103.6501.91M
19 Dec 253.6103.7653.4503.4508.57M
18 Dec 253.6703.7103.5103.6001.35M
17 Dec 253.5203.7103.4703.6401.94M
16 Dec 253.4003.6603.3403.5205.11M
15 Dec 253.6803.8003.4103.4304.05M
12 Dec 253.4003.6203.3703.6001.81M

PROFILE

Name:Erasca Inc
About:Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:3115 Merryfield Row, San Diego, CA, United States, 92121
Website:https://www.erasca.com
CUSIP:29479A108
CIK:0001761918
ISIN:US29479A1088
FIGI:BBG00MTSR883

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.45 
Forward P/E:-3.18 
PEG Ratio:0.06 
Price to Book:1.79 
Return on Assets:-0.18 
Return on Equity:-0.31 
EPS Ratio:-0.39 
Shares:283.67M 
Market Cap:988.59M 

TECHNICAL INDICATORS

MA5:3.480.1%
MA10:3.521.0%
MA20:3.363.6%
MA50:2.8621.8%
MA100:2.3349.4%
MA200:1.8686.9%
STO9:21.95
STO14:40.74
RSI14:56.52
WPR14:-43.59
MTM14:0.14
ROC14:0.04 
ATR:0.25 
Week High:3.778.0%
Week Low:3.325.0%
Month High:3.809.0%
Month Low:2.8186.9%
Year High:3.809.0%
Year Low:1.01245.0%